Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assists Nuevolution in connection with Amgen’s cash offer
Mandate

Vinge assists Nuevolution in connection with Amgen’s cash offer

May 22, 2019 Capital Markets and Public M&A

Vinge has assisted Nuevolution AB (publ) (“Nuevolution”) in connection with the cash offer to the shareholders in Nuevolution by Amgen Inc. (“Amgen”).

Nuevolution is a molecule drug discovery biotech company, listed on Nasdaq Stockholm. 

Amgen is one of the world’s leading biotechnology companies, with a vision deeply rooted in innovative science. Amgen’s shares are listed on Nasdaq in the United States.

Amgen offers SEK 32.50 in cash for every share in Nuevolution. The offer value amounts to approximately SEK 1,610 million.
 
Vinge’s team has primarily consisted of David Andersson, Dain Hård Nevonen, Ludvig Frithiof and William Kåge.

Related

Vinge advises on the sale of Compab to Tången

 Vinge has advised the owners of Compab Energiteknik in connection with the sale of 80 per cent of the shares to Tången Industrikapital. Compab, which has a turnover of approximately SEK 100 million, sells, installs and services, amongst other things, steam and hot-water boilers as well as burners for the industrial sector.
October 26, 2026

Vinge advises Capio on the acquisition of Rehabhotellet Sthlm AB

 Rehabhotellet i Sthlm AB provides advanced home healthcare and specialized inpatient palliative care within the Stockholm Region.
October 26, 2026

Vinge advises Ikano Bank on acquisition of loan portfolio from Entercard

 Vinge has advised Ikano Bank AB (publ) on the acquisition of a portfolio of performing consumer loans from Entercard Group AB. As at 30 September 2026, the contractual amount of the loans totalled approximately SEK 7 billion.
October 26, 2026